GlyCosmos Glycolipids
Glycolipid entries from the LIPID MAPS Structure Database (LMSD).
| Database | Last Updated |
|---|---|
| ChEBI | February 3, 2022 |
| KEGG | February 3, 2022 |
| LIPID MAPS Structure Database | February 3, 2022 |
| LipidBank | February 3, 2022 |
| PubChem | February 3, 2022 |
| Main Class | Sub Class | LM ID | Common Name | LipidBank ID | KEGG ID | PubChem CID | ChEBI ID | Exact Mass ▼ | Formula |
|---|---|---|---|---|---|---|---|---|---|
|
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
B-IV antigen(d18:1/24:0)
|
3050.49321
|
C134H235N5O71
|
|||||
|
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
B-IV antigen(d18:1/24:1(15Z))
|
3048.47756
|
C134H233N5O71
|
|||||
|
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
3039.415689
|
C130H226N6O73
|
||||||
|
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
3039.415689
|
C130H226N6O73
|
||||||
|
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
B-IV antigen(d18:1/22:0)
|
3022.46191
|
C132H231N5O71
|
|||||
|
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
3011.384389
|
C128H222N6O73
|
||||||
|
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
3011.384389
|
C128H222N6O73
|
||||||
|
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
B-IV antigen(d18:1/20:0)
|
2994.43061
|
C130H227N5O71
|
|||||
|
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
2989.488064
|
C132H232N6O68
|
||||||
|
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
2989.488064
|
C132H232N6O68
|
Displaying entries 31 - 40 of 6008 in total
To see the latest features, please visit our beta site.
International Collaboration
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Acknowledgements
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
